Johnson & Johnson (JNJ) Stock News

Johnson & Johnson announced promising first clinical data from a Phase 1b study of JNJ-90014496, a novel dual-targeting CD19/CD20 CAR T-cell therapy for relapsed/refractory large B-cell lymphoma. The therapy showed impressive efficacy with 80% complete response rate in patients with one prior treatment line and 75% in those with two or more prior treatments. At the recommended Phase 2 dose of 75 million CAR+ T-cells, the therapy demonstrated a favorable safety profile with no Grade 3/4 cytokine release syndrome observed. The study involved 22 patients for efficacy assessment, achieving 100% objective response rate in single prior therapy patients and 92% in multiple prior therapy patients. This development represents a potential advancement over current single-antigen CAR T therapies, which typically achieve only 40% long-term remission rates.

Johnson & Johnson announced promising Phase 1b data for bleximenib (JNJ-75276617), an investigational selective menin inhibitor, in combination with venetoclax and azacitidine for acute myeloid leukemia (AML). The study evaluated 125 patients with KMT2A gene rearrangements or NPM1 gene mutations. At the recommended Phase 2 dose of 100mg twice daily, relapsed/refractory AML patients showed an 82% overall response rate and 59% complete response rate, while newly diagnosed patients achieved 90% and 75% respectively. The safety profile was favorable, with only 4% of patients experiencing differentiation syndrome and no significant QTc prolongation. Common adverse events included nausea (65%), thrombocytopenia (61%), neutropenia (59%), and anemia (49%).

Johnson & Johnson announced significant findings from their Phase 3b APEX study for TREMFYA (guselkumab) in treating active psoriatic arthritis (PsA). The study demonstrated TREMFYA's superior efficacy in inhibiting joint structural damage compared to placebo, with mean vdH-S score changes of 0.55 (Q4W) and 0.54 (Q8W) versus 1.35 for placebo. The drug showed impressive results with over 40% of treated patients achieving ACR50 at Week 24, and approximately 67-68% achieving ACR20. Notably, 63-67% of TREMFYA-treated patients experienced no radiographic progression compared to 53% in the placebo group. The drug also demonstrated significant skin clearance benefits, with 68-73% of treated patients achieving clear or almost clear skin (IGA score 0/1) versus 31% for placebo. TREMFYA maintains its established safety profile with no new safety concerns identified.

Johnson & Johnson (NYSE: JNJ) has announced the election of Daniel Pinto, President of JPMorganChase, to its Board of Directors. Pinto brings extensive financial expertise and deep understanding of global capital markets to JNJ's board. CEO Joaquin Duato emphasized that Pinto's unique perspective and experience will be valuable as the company continues to invest in healthcare innovation. Pinto expressed admiration for JNJ's commitment to scientific innovation and improving health outcomes, stating his honor in joining the board to serve alongside members dedicated to improving global health and well-being.

Johnson & Johnson announced groundbreaking long-term data for CARVYKTI in treating relapsed/refractory multiple myeloma. The CARTITUDE-1 study showed 33% of patients (32 out of 97) achieved progression-free survival of 5+ years with just a single infusion, requiring no maintenance therapy. The median overall survival reached 60.7 months, with 12 patients maintaining minimal residual disease negativity throughout the five-year follow-up. The safety profile remained consistent with no new safety signals, except for two new solid tumor cases. Additional CARTITUDE-4 study data demonstrated CARVYKTI's superior progression-free and overall survival benefits across various patient subgroups, including those with standard and high-risk cytogenetics.

Johnson & Johnson announced impressive clinical trial results for DARZALEX FASPRO in multiple myeloma treatment. The Phase 3 PERSEUS study showed 95.3% progression-free survival at 48 months in transplant-eligible patients, with over 55.8% achieving sustained MRD negativity for 24+ months using DARZALEX FASPRO-based regimen (D-VRd) followed by D-R maintenance. The Phase 3 CEPHEUS study in transplant-ineligible patients demonstrated 60.4% overall MRD negativity and 69% progression-free survival at 54 months with D-VRd treatment. The drug showed significant improvements over standard treatments across multiple efficacy measures, with consistent safety profiles, positioning DARZALEX FASPRO as a cornerstone therapy for newly diagnosed multiple myeloma patients.

Johnson & Johnson (JNJ) announced promising Phase 1 trial results for JNJ-79635322 (JNJ-5322), a novel trispecific antibody for treating relapsed or refractory multiple myeloma. The trial showed an impressive 86.1% overall response rate among 36 patients at the recommended Phase 2 dose, with 100% response in BCMA and GPRC5D therapy-naive patients. JNJ-5322 uniquely targets three distinct proteins: BCMA and GPRC5D on myeloma cells and CD3 on T-cells. The study involved 126 patients with 8.2 months median follow-up. While cytokine release syndrome occurred in 59% of patients, no cases were Grade 3 or higher. However, 28% experienced Grade 3+ infections, and four treatment-related deaths were reported, including one from adenoviral encephalitis.

Johnson & Johnson announced breakthrough results from Phase 3 AMPLITUDE study evaluating AKEEGA® (niraparib and abiraterone acetate) combination therapy in metastatic castration-sensitive prostate cancer (mCSPC) patients with HRR genetic alterations. The study demonstrated a 48% reduction in disease progression risk for BRCA-altered patients and 37% reduction for HRR-altered patients. The treatment showed significant improvements in radiographic progression-free survival (rPFS) and delayed symptom progression. In BRCA-altered patients, median rPFS was not reached compared to 26 months with placebo. The combination also showed an early trend toward improved overall survival. While Grade 3/4 adverse events were more frequent in the treatment group (75% vs 59%), discontinuation rates remained low at 14.7%. This marks the first Phase 3 data showing clinical improvement with a PARP-based combination in mCSPC.

Johnson & Johnson (NYSE: JNJ) has scheduled an investor conference call to discuss its second-quarter 2025 results on Wednesday, July 16th at 8:30 a.m. (Eastern Time). The call will be hosted by key executives including CEO Joaquin Duato, CFO Joseph J. Wolk, and VP of Investor Relations Darren Snellgrove.

Investors can access the call via webcast at www.investor.jnj.com or by telephone (U.S.: 877-869-3847, International: 201-689-8261). The earnings press release will be available at 6:45 a.m. ET on the day of the call. A replay will be accessible until July 30th. The company has also announced its third-quarter earnings call date for October 14th, 2025.